Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 | Synapse
September 10, 2025Open Access
Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Key Points
Findings reveal that lag-3+cd8+ subgroups are present in both treatment arms, highlighting potential immune responses.
Prevalence data indicates a distinct distribution of lag-3+cd8+ among patients undergoing different treatments.
Analysis utilized biomarkers to assess T-cell subsets in relation to relatlimab and nivolumab therapies.
Understanding these subgroup dynamics may inform future therapeutic strategies for advanced melanoma cases.
Abstract
Prevalence of LAG-3+CD8+ subgroups in the NIVO + RELA and NIVO arms.